利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化*

doi:10.3969/j.issn.1672-5069.2020.02.014

Abstract

Abstract: Objective Objective The aim of this study was to investigate the efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Methods 90 patients with NAFLD and T2DM were recruited in our hospital between January 2014 and December 2018,and were randomly divided into control (n=45) and observation group (n=45). They were treated with metformin or metformin and liraglutide combination for 12 weeks. Fasting blood glucose (FPG) , postprandial 2 h blood glucose (2hPPG) and glycosylated hemoglobin (HbA1c), blood lipid index and serum hyaluronic acid (HA), laminin (LN), type IV collagen (CIV), and type III procollagen (PIIIP) were assayed. The parameters of brachial artery, such as T1 and T2, endothelium-dependent relaxation (EDR) and endothelium-non-dependent relaxation (END) were recorded by high-resolution ultrasound. Results At the end of three-month treatment, the FPGs in the observation and control group were (7.3±1.9) mmol/L vs. (8.6±1.8) mmol/L, and the 2 hPPG were (9.8±2.3) mmol/L vs. (11.4±2.2) mmol, and HbA1c were (7.2±1.0)% vs. (8.3±1.2)%, respectively, all significantly different (P<0.05); serum TC levels were (4.8±0.9) mmol/L vs. (5.6±1.2) mmol/L, TG were (1.5±0.4) mmol/L vs. (2.0±0.6) mmol/L, LDL-C were (2.0±0.6) mmol/L vs. (2.9±0.7) mmol/L, and HDL-C was (1.6±0.3)mmol/L vs. (1.3±0.2)mmol/L, all significantly different (P<0.05); T1 were (56.1±6.5)s vs. (62.9±5.8)s, EDR were (7.8±1.0)% vs. (5.2±0.8)%, and END were (21.3±2.9)% vs. (17.2±2.5)%, all significantly different (P<0.05); serum HA were (70.3±9.2) ng/ml vs. (85.9±10.3) ng/ml, CIV were (50.2±0.7) ng/ml vs. (67.3±0.9) ng/ml, and PIIINP were (6.2±). 0.6) ng/ml vs. (8.3±0.5) ng/ml, all significantly different (P<0.05) in the two groups. Conclusion Liraglutide is efficacious in treatment of patients with NAFLD and mellitus, which could effectively decrease blood sugar levels, improve vascular endothelial functions and correct lipid metabolism disorder.

Key words: Nonalcoholic fatty liver diseases, Type 2 diabetes mellitus, Liraglutide, Brachial artery, Vascular endothelium functions, Therapy

Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.

References

[1] 邓晓龙,朱红霞,王敏哲,等.利拉鲁肽应用于2型糖尿病合并非酒精性脂肪肝患者的疗效及安全性分析.标记免疫分析与临床,2016,23(8):911-913.
[2] Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res, 2015, 45(3):269-278.
[3] Rizvi A A, Patti A M, Giglio R V, et al. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther, 2015, 15(10):1391.
[4] Petit J M, Cercueil J P, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab, 2017, 102(2):407-415.
[5] Feng W, Gao C, Bi Y, et al. A randomized trial comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease. J Diabetes, 2017, 9(8):800-809.
[6] Bloomgarden Z. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control. J Diabetes, 2017, 9(8):722-723.
[7] 杨帆,李钶,蒋晓岚,等.利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究.重庆医学,2016,45(25):3493-3495.
[8] Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol, 2017, 10(7):1.
[9] Biberoglu E , Kirbas A , DaglarFeng W H, et al. Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig, 2019, 10(2):399-407.
[10] Dyson J K, Anstee Q M, Mcpherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol, 2014, 5(4):277-286.
[11] 杜玉茗,张雷,郭宇,等.利拉鲁肽对2型糖尿病合并非酒精性脂肪肝的防治作用.中国老年学杂志,2017,37(21):5282-5284.
[12] Tong W, Ju L, Qiu M, et al. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway. Hepatol Res, 2016, 46(9):933-943.
[13] Fukuhara T, Hyogo H, Ochi H, et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology, 2014, 61(130):323-328.
[14] Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol, 2016, 2(1):1-9.
[15] Wong V W, Wong G L. A LEAN treatment for non-alcoholic steatohepatitis. Lancet, 2016, 387(10019):628-630.
[16] García D E, Guagnozzi D, Gutiérrez V, et al. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinol Nutr, 2016, 63(5):194-201.
[17] Guss D A, Mohanty S R. Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study. Hepatobiliary Surg Nutr, 2016, 5(6):515.
[18] 刘丽,张宇.利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪沉积的影响.肝脏,2018,23(4):338-340.
[19] Feng W, Gao C, Bi Y, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease. J Diabetes, 2017, 9(8):800-809.
[20] Yan H M, Xia M F, Wang Y, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. Plos One, 2015, 10(8):e0134172.

Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.
[2]	Zhang Xiaowei, Zhong Rui. Short-term efficacy and tolerance ofsofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection [J]. Journal of Practical Hepatology, 2020, 23(2): 191-194.
[3]	Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM [J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.
[4]	Wang Hongxue, Zhu Qingjing, Zhang Yujuan , et al. Efficacy of cetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries [J]. Journal of Practical Hepatology, 2020, 23(2): 227-230.
[5]	Li Yongchao, Ren Hongjun, Liu Lei, et al. Clinical efficacy of double plasma adsorption and plasma exchange in treatment of patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2020, 23(2): 236-239.
[6]	Jia Jiao, Wang Fang, Zhang Bo, et al. Efficacy of ursodeoxycholic acid combined with calcitriol in treatment of patients with primary biliary cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 240-243.
[7]	Zhang Huiyong, Wu Xiuxin, Xu Chengrun. Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites [J]. Journal of Practical Hepatology, 2020, 23(2): 244-247.
[8]	Hu Hong, Liao Yunguo, Wei Xin, et al. Clinical comparison of ¹²⁵I seed implantation or 3DCRT and TACE combination in treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2020, 23(2): 268-271.
[9]	Fan Wenhan, Luo Yiping, Li Chengzhong. Application of steroids in treatment of patients with liver failure [J]. Journal of Practical Hepatology, 2020, 23(1): 7-9.
[10]	Li Yonghua, Sun Yanfen, Wang Jiajia, et al. Efficacy of entecavir and matrine combination therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(1): 22-25.
[11]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[12]	Wei Zhongcao, Liu Na, Xing Xin, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis [J]. Journal of Practical Hepatology, 2020, 23(1): 46-49.
[13]	Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.
[14]	Sun Hongju, Wang Yanyan, Xu Congcong, et al. Efficacy of tiopronin and metoprolol combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2020, 23(1): 54-57.
[15]	Wang Jianhui, Guo Hongdan, Kong Jingjing, et al. Clinical characteristics and risk factors ofdrug-induced liver injury caused by antituberculosis therapy [J]. Journal of Practical Hepatology, 2020, 23(1): 58-61.